Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis

• Published in: Journal of medical economics Vol. 26; no. 1; pp. 1061 - 1071
• Main Authors: Patel, Mikin V., Davies, Heather, Williams, Abimbola O., Bromilow, Tom, Baker, Hannah, Mealing, Stuart, Holmes, Hayden, Anderson, Nicholas, Ahmed, Osman
• Format: Journal Article
• Language: English
• Published: 31.12.2023
• ISSN: 1369-6998; 1941-837X
• DOI: 10.1080/13696998.2023.2248840

OBJECTIVESTo assess the cost-effectiveness of transarterial radioembolization (TARE) versus conventional transarterial chemoembolization (cTACE) and drug-eluting beads chemoembolization (DEE-TACE) for patients with unresectable early- to intermediate-stage hepatocellular carcinoma (HCC).DESIGNA cohort-based Markov model with a five-year time horizon was developed to evaluate the cost-effectiveness of the three embolization treatments. Upon entering the model, patients with HCC received either TARE or one of the two other embolization treatments. Patients remained in a "watch and wait" state for tumor downstaging that allowed them to move to health states such as liver transplant, resection, systemic therapies, or cure. Clinical input parameters were retrieved from the published literature, and where values could not be sourced, assumptions were made and validated by clinical experts. Health benefits were quantified using quality-adjusted life years (QALYs). Cost input parameters were obtained from various sources, including the Medicare Cost Report, IBM® Micromedex RED BOOK, and published literature.RESULTSAt five years, TARE was found to be cost-saving (saving $15,779 per person compared to cTACE) and produced 0.33 more QALYs per person than cTACE. TARE cost $13,696 more but produced 0.33 more QALYs than DEE-TACE, with an incremental cost-effectiveness ratio of $41,474 per QALY gained at five years. After accounting for parameter uncertainty, the likelihood of TARE being cost-effective was at least 90% against all comparators at a cost-effectiveness threshold of $100,000 per QALY gained.CONCLUSIONSTARE produces more QALYs than cTACE and DEE-TACE, with a high probability of being cost-effective against both comparators.